Pfizer hopes high on oncology portfolio by acquisition of Array Biopharma
Pfizer and Array Biopharma announced that they have agreed to merge Pfizer and Array Biopharma. Under the acquisition, Pfizer will acquire Array Biopharma by paying $48 per share in cash, accounting a total of $11.4 billion. Array Biopharma has several small molecules in pipeline targeted at cancer and other diseases of high unmet needs.
Array Biopharma’s portfolio includes Braftovi and Mektovi combination indicated for the patients suffering from BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma. The combination is targeted at other solid tumors, including BRAF-mutant metastatic colorectal cancer.
Apart form combination treatment for metastatic melanoma, Array Biopharma has a broad portfolio with best-in-class and first-in-class cancer products.